Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Risk of lymphoma: inflammatory bowel disease and immunomodulators
    • Yeng S Ang, Consultant Gastroenterologist
    • Other Contributors:
      • Farrell RJ, Centre for Inflammatory Bowel Disease, Division of Gastroenterology, Beth Israel Deaconess Medical Centre, Harvard Medical School, Boston, MA, USA.

    Dear Editor,

    We read with great interest the meta-analysis by Kandiel et al., (Gut 2005; 54: 1121-1125) the purpose of which was to provide a more precise estimate of the relative risk of lymphoma among inflammatory bowel disease (IBD) patients treated with azathioprine or 6-mercaptopurine (6-MP). Based on the six studies included in their meta-analysis, Kandiel et al., determined that the risk of lymphoma among...

    Show More
    Conflict of Interest:
    None declared.